ARTICLE | Clinical News
Bertilimumab: Phase II started
September 29, 2014 7:00 AM UTC
Immune Pharmaceuticals began a double blind, placebo-controlled, Israeli Phase II trial to evaluate 3 doses of 10 mg/kg IV bertilimumab given 2 weeks apart in about 42 adults with UC. Immune Pharmaceu...